GLP-1 agonists are medications that imitate these hormones, earning them the name incretin mimetics. Originally developed to treat type 2 diabetes, GLP-1s trigger insulin release and block glucagon to prevent diabetic ketoacidosis
Again, orforglipron is still being studied and in late clinical trials, but heres the expected timeline: Eli Lilly plans to submit it to the FDA in late 2025 for approval for weight loss in adults with a BMI of 30 or higher, or 27 and higher with a related health condition
The medication must be prescribed by a licensed practitioner and intended for personal consumption, not resale
Supplementing GSH to the cell medium has been shown to aggravate this effect 16
In other GLP-1 medications like Ozempic, Trulicity, or Victoza, fatigue is less frequently reported or not specifically listed as a common side effect in FDA prescribing information